wound-congress-dermatology-congress-2018-keynote

8 / 9

Volume 4 Clinical Pediatric Dermatology
ISSN: 2472-0143
Page 35
Notes:
October 15-16, 2018 Rome, Italy
&
JOINT EVENT
14th International Conference on Clinical Dermatology
5th International Conference on
Advances in Skin, Wound Care and Tissue Science
Wound Congress 2018 &
Clinical Dermatology Congress 2018
October 15-16, 2018
Topical medical cannabis: A new epigenetic paradigm for wound management
Statement of the Problem: The endocannabinoid system is ubiquitous throughout the human body and has recently been
found to have a significant representation throughout the integumentary system, both cutaneous membranes and mucous
membranes. Topical Medical Cannabis (TMC) based medicines are intrinsically lipophilic and contain both delta-9-
tetrahydrocannabinol (THC) and Cannabidiol (CBD) in varying proportions. Given that wound beds are largely lipophilic
absorption of lipophilic agents, such as cannabinoids, is enhanced.
Methodology & Theoretical Orientation: A series of n=1 trials were initiated on a cohort of stalled recalcitrant wounds,
composed of cases of greater than 12 months duration, were treated with TMC based medicines. All cases were previously
afforded with all available Evidence-Based treatments that conformed with local best practices and wound-bed preparation
principles. Ten cases were studies for wound analgesia, 10 cases for wound healing, and 4 cases for diseasemodulation. Etiologies
represented within the cohort under study included: Pyoderma Gangrenosum, Leukocytoclastic Vasculitis, Cryoglobulinemia,
Antiphospholipid syndrome, Sickle Cell Disease, Lichen Simplex Chronicus, Bowen’s Disease, and Squamous Cell Cancer.
Clinically significant analgesia, wound healing, and disease was noted in all cases. The TMC medicines were applied directly
applied to wound beds. TMC was very well tolerated and no adverse reactions were observed.
Conclusion & Significance: The highly positive results observed in a cohort of the most challenging recalcitrant cases provokes
realistic interpolation that TMC based Medicines may be effective for a broader context within Wound Management. The
endocannabinoid system is a viable Epigenetic target and platform for exploring therapeutic options for skin and wound
conditions. Therapies based on Topical Medical Cannabis that interact at the level of the endocannabinoid system have
significant potential to improve the 3 main target outcomes in wound management, namely, wound analgesia, wound healing,
and disease modulation that includes antineoplastic actions.
Biography
Vincent Maida is a consultant in Palliative Medicine & Wound Management at the William Osler Health System in Toronto. He obtained his medical degree from the Uni-
versity of Toronto. He was promoted to Associate Professor at the University of Toronto in 2011. Maida completed his MSc in Wound Management in 2010, his Medical
Teachers Certificate in 2011, and his certificate in Patient Safety and Quality Improvement in 2014, all at the University of Toronto. Maida is an active researcher with partic-
ular interests in pain and symptom management, wound management, prognosis, and medical education. Over the past 10 years, he has published 4 textbook chapters,
over 30 original research papers, created numerous original conceptual innovations in Palliative Medicine and Wound Management, as well as delivering over 100 national
and international presentations on 5 continents, 14 countries, and over 50 cities.
Vincent Maida
William Osler Health System, Canada
Vincent Maida, Clin Pediatr Dermatol 2018, Volume 4
DOI: 10.21767/2472-0143-C2-004